Latest Headlines

  1. NOXXON Announces The Completion Of The First-In-Human Clinical Trial With Spiegelmer NOX-A12
    5/3/2010
    NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer technology, announced today the successful completion of the first-in-human clinical trial with Spiegelmer NOX-A12. This Phase I study was designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy individuals following intravenous administration of the stromal cell-derived factor-1 (SDF-1) antagonizing Spiegelmer® NOX-A12. Final data analysis demonstrated an excellent safety and tolerability up to the
  2. ImmunoCellular Files Orphan Drug Application For ICT-107
    5/3/2010
    ImmunoCellular Therapeutics announced recently it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors
  3. Sistemic Launches New Range Of Drug Discovery Research SistemRNATM (v2) Profiles
    5/3/2010
    Sistemic recently announced immediate availability new SistemRNA™ product lines in key therapeutic areas including oncology and inflammation. These new product additions will strengthen strategic decision making at critical stages of the drug discovery and development process, helping to realise the full value of client's compound assets
  4. Compugen Announces New Drug Discovery Platform To Predict Peptides That Block Protein – Protein Interactions
    4/22/2010
    Compugen Ltd. announced today the development of its Protein-Protein Interaction Blockers (PPI Blockers) Discovery Platform, designed for the prediction of peptides to block disease associated protein-protein interactions. In a pilot validation run, predicted peptides showed positive results for drug targets in two cancer related pathways of interest to the industry
  5. Sparta Systems Unveils TrackWise® Audit Execution Package
    4/21/2010
    Sparta Systems, Inc., the maker of TrackWise® software and the market leader in enterprise quality and compliance management solutions, recently announced the release of its TrackWise Audit Execution Package.
  6. BMG LABTECH Is Proud To Be A Bronze Sponsor Of The SBS Conference 2010
    4/7/2010
    See BMG LABTECH's full range of innovative microplate reading solutions as well as the newest, most comprehensive Data Analysis Software, MARS, or discuss your assay needs personally with our applications scientists at booth 817.
  7. Elsevier Adds FDA Advisory Committee Content To PharmaPendium
    4/1/2010
    Offers Preclinical, Clinical Drug Development and Regulatory Affairs More Access to Comparative Data PharmaPendium (www.info.pharmapendium.com/), Elsevier announces a new release that adds extensive FDA Advisory Committee content to the online resource for authoritative preclinical, clinical and post-market drug information
  8. AgaMatrix And Sanofi-Aventis Enter Global Diabetes Partnership
    4/1/2010
    AgaMatrix, Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions
  9. Patents Awarded To Metabolon For Metabolomics Methods
    3/31/2010
    Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, announced recently the grant of US Patent 7,682,783 and US Patent 7,682,784 entitled "Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics". The USPTO awarded the patents to Metabolon on March 23, 2010. The issued claims in the new patents are for uses of metabolomics to identify diagnostic biomarkers for depression and schizophrenia by profiling classes of metabolites in a sample.
  10. More Than 150 Companies Included In The Program For The NYBA 2010 Annual Meeting, April 19-20 In NYC
    3/30/2010
    New York Biotechnology Association (NYBA), the voice of New York State's biotechnology industry, recently announced the full program for the NYBA 2010 Annual Meeting, April 19-20, at the Marriott Marquis Hotel in New York City. Speakers representing more than 100 companies will discussion the issues and opportunities available to New York's bioscience industry. The NYBA 2010 Annual Meeting program, which can be seen at www.nyba.org, will highlight more than 30 panel sessions on key

First 4 5 6 7 8 9 10 10 (Last)